Format
Sort by

Send to

Choose Destination

Search results

Items: 9

1.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators..

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

2.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group..

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

3.

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators..

Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002.

PMID:
25965710
4.

Sarcocystis spp. in llamas (Lama glama) in Southern Bolivia: a cross sectional study of the prevalence, risk factors and loss in income caused by carcass downgrades.

Rooney AL, Limon G, Vides H, Cortez A, Guitian J.

Prev Vet Med. 2014 Oct 1;116(3):296-304. doi: 10.1016/j.prevetmed.2013.11.014.

PMID:
24380570
5.

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.

Rosen JB, Jimenez JG, Pirags V, Vides H, Massaad R, Hanson ME, Brudi P, Triscari J.

Lipids Health Dis. 2013 Jul 16;12:103. doi: 10.1186/1476-511X-12-103.

6.

A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.

Rosen JB, Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, McPeters G, Brudi P, Triscari J.

Diab Vasc Dis Res. 2013 May;10(3):277-86. doi: 10.1177/1479164112465212.

PMID:
23288881
7.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators..

N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845.

8.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team..

Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3.

PMID:
19501900
9.

Diabetes and social conditions in Estonia. A population-based study.

Vides H, Nilsson PM, Sarapuu V, Podar T, Isacsson A, Scherstén BF.

Eur J Public Health. 2001 Mar;11(1):60-4.

PMID:
11276573
Items per page

Supplemental Content

Loading ...
Support Center